Table 1.
Clinical characteristics of patientsa
| Characteristic | Broad cross-neutralizer patients |
Control patients |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 181 | 308 | 363 | 488 | 528 | 541 | 108 | 279 | 296 | 326 | 405 | 423 | |
| Risk group | MSM | MSM | MSM | Unknown | MSM | MSM | IDU | MSM | MSM | MSM | HTX | MSM |
| Peak VL (log) | 4.60 | 4.44 | 3.90 | 3.71 | 5.01 | 4.89 | 5.69 | 5.63 | 5.08 | 5.04 | 4.23 | 4.69 |
| Nadir CD4+ level (cells/μl) | 266 | 410 | 537 | 291 | 240 | 286 | 219 | 260 | 305 | 340 | 408 | 525 |
| Nadir CD8+ level (cells/μl) | 285 | 948 | 661 | 630 | 644 | 390 | 394 | 549 | 847 | 458 | 377 | 374 |
| TPS (months) | 185.3 | 127.4 | 97.3 | 65.6 | 62 | 67.4 | 225.6 | 84.6 | 91.3 | 97.7 | 85.9 | 78.4 |
| Beginning of the study (−71 to −37 months)b | ||||||||||||
| Age (yrs) | 57 | 38 | 34 | 36 | 28 | 54 | 42 | 31 | 36 | 36 | 34 | 25 |
| cART | — | — | — | — | — | — | — | — | — | — | — | — |
| VL (log) | 4.04 | 3.31 | 3.48 | 2.6 | 4.9 | 4.51 | 4.75 | 3.94 | 3.53 | 3.86 | 2.81 | 4.04 |
| No. of CD4+ T cells/μl | 567 | 506 | 758 | 646 | 556 | 606 | 595 | 645 | 509 | 425 | 436 | 600 |
| No. of CD8+ T cells/μl | 756 | 1,720 | 924 | 1,115 | 1,290 | ND | 1,388 | 1,290 | 1,136 | 962 | 377 | 726 |
| Time zeroc | ||||||||||||
| cART | ATP | ATP | — | ATP | — | ATP | ATP | — | — | ATP | — | — |
| VL (log)d | <1.7 | <1.7 | 3.87 | <1.7 | 4.43 | <1.7 | <1.7 | 4.94 | 4.61 | <1.7 | 4.24 | 3.51 |
| No. of CD4+ T cells/μl | 437 | 530 | 581 | 291 | 759 | 499 | 759 | 399 | 331 | 703 | 590 | 666 |
| No. of CD8+ T cells/μl | 857 | 1,698 | 664 | 1,029 | 1,029 | 576 | 1,621 | 1,386 | 1,284 | 836 | 859 | 1,030 |
| End of the study (18 to 34 months)e | ||||||||||||
| cART | ATP | ATP | — | ATP | ATP | ATP | ATP | ATP | ATP | ATP | ATP | — |
| VL (log)d | <1.56 | <1.56 | 3.49 | <1.56 | <1.56 | <1.56 | <1.7 | 1.85 | 2.85 | <1.7 | <1.7 | 4.21 |
| No. of CD4+ T cells/μl | 539 | 819 | 664 | 402 | 638 | 484 | 688 | 514 | 593 | 551 | 600 | 525 |
| No. of CD8+ T cells/μl | 1,174 | 1,580 | 979 | 816 | 646 | 390 | 1,383 | 1,601 | 2,093 | 893 | 570 | 1,047 |
a
All patients were male. MSM, men that have sex with men; IDU, injecting drug user; HTX, heterosexual; VL, viral load; TPS, time elapsed between first HIV-1-positive serology and time zero; ATP: Atripla (efavirenz + emtricitabine + tenofovir). —, untreated.
b
Time (months) before the last time analyzed in the previous study.
c
Last time (months) included in the previous study.
d
The limit of detection was 1.7 log or 1.56 log (corresponding to 50 or 36 copies/ml, respectively), depending on the commercial kit used.
e
Time (months) after the last time included in the previous study (15).